|
|
|
|
|
What to Expect from the Upcoming 2025 European Association of Urology Congress |
|
|
|
|
| CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
|
| Press Release
|
|
|
|
|
|
|
|
| Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress |
| Press Release |
|
|
|
|
|
|
|
|
Rapid-Fire Debates: Common Problems and Controversies in Bladder Cancer
Thematic Session - 04:45 AM - 06:45 AM EST
|
|
|
|
|
Rapid-Fire Debate 1 Patient with High-Risk NMIBC: Is BCG Still the Best Option in 2025?
Presented By: Gianluca Giannarini, MD
Presented By: Laura S Mertens, MD
|
|
|
|
|
Rapid-Fire Debate 2 BCG Unresponsive Disease: How Much Risk Can My Patient Tolerate?
Presented By: Maria Carmen Mir, MD, PhD
Presented By: Ashish Kamat, MD, MBBS
|
|
|
|
|
Rapid-Fire Debate 4 Patient with T2N3 Disease: Is There Any Role for Surgical Consolidation If CR After 6 Cycles GC? What If Only PR in Nodes?
Presented By: Shilpa Gupta, MD
Presented By: Félix Guerrero-Ramos, MD, PhD, FEBU
Rapid-Fire Debate 5 Management of Positive Soft Tissue Margins After Radical Cystectomy. What About Isolated Pelvic Recurrences After RC?
Presented By: Comron Hassanzadeh, MD, MPH
Presented By: Andrea Necchi, MD
|
|
|
|
|
|
|
|
|
|
Rapid-Fire Debate 6 Patient with High-Grade Upper Tract Disease: Neoadjuvant or Adjuvant Systemic Therapy?Presented By: Alison Birtle, MRCP, FRCR, MD
Presented By: Arnulf Stenzl, MD
|
|
|
|
|
|
|
| Biomarkers to Guide Peri-Operative Management in Urooncology - Plenary - 02:00 AM - 03:45 AM EST
|
|
|
|
|
State-of-the-Art Lecture Current Landscape of Peri-Operative Therapies in Kidney and Bladder Cancer
Presented By: Philippe Spiess, MD
|
|
|
|
|
State-of-the-Art Lecture Current Landscape of Peri-Operative Therapies in Prostate Cancer
Presented By: Martin Gleave, CM, MD, FRCSC, FACS,
|
|
|
|
|
State-of-the-art lecture Imaging as a biomarker
Presented By: Valeria Panebianco, MD
|
|
|
|
|
State-of-the-Art Lecture Biomarker Discovery: From Bench to Bedside
Presented By: Lars Dyrskjøt, PhD, MSc
|
|
|
|
|
| Extended abstract session I - EAU Lab: Abstract Session - 04:30 AM - 06:00 AM EST
|
|
|
|
|
State-of-the-Art Lecture ctDNA Testing for Guiding Treatment Decisions in GU Cancers
Presented By: Alexander Wyatt, PhD, BSc
|
|
|
|
|
|
|
| Intravesical Therapy for Bladder Cancer Thematic Session - 07:30 AM - 09:00 AM EST |
|
|
|
|
State-of-the-Art Lecture Decoding HR-NMIBC: The Clinical Significance of Molecular Profiling
Presented By: Tahlita Zuiverloon, MD, PhD
|
|
|
|
|
State-of-the-Art Lecture TAR, a Novel Intravesical Drug Delivery System
Presented By: Sima Porten, MD, MPH
|
|
|
|
|
| Systemic Treatment of Metastatic Prostate Cancer - Abstract Session 31 - 07:45 AM - 09:15 AM EST |
|
|
|
|
Impact of Baseline Prostate-Specific Antigen on Clinical Outcomes in Patients with mHSPC Treated with Darolutamide Triplet Therapy in ARASENS
Presented By: Alicia Morgans, MD, MPH
|
|
|
|
|
Impact of Bone Protecting Agents on the Efficacy and Safety of Enzalutamide vs Combination of Radium-223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Patients with Bone mCRPC: Sub-Goup Analysis from EORTC-GUCG 1333/PEACE-3, an EORTC/CTI/CUOG/LACOG/UNICANCER Randomized Phase III Study
Presented By: Fred Saad, MD, FRCS
|
|
|
|
|
| Hot Topics in Renal Cell Carcinoma Management Thematic Session - 09:15AM - 10:45 AM EST |
|
|
|
|
State-of-the-Art Lecture Risk Stratification for Patients with mRCC: Is There a Need for New Approaches?
Presented By: Géraldine Pignot, MD
|
|
|
|
|
State-of-the-Art Lecture Neoadjuvant Strategies in Locally Advanced Renal Cancer
Presented By: Axel Bex, MD, PhD
|
|
|
|
|
|
|
| Optimising the Patient Journey: From Prehabilitation to Rehabilitation in Urologic Surgery Plenary Session - 02:00 AM - 04:00 AM EST |
|
|
|
|
Prehabilitation: The Impact of Exercise, Personalised Programmes, and Digital Devices
Presented By: Sarah Psutka MD, MSc
|
|
|
|
|
Prehabilitation: Diet, Sleep and Psychological Preparation
Presented By: Axel Bex, MD, PhD
|
|
|
|
|
| NMIBC: Innovations and Outcomes 1 Abstract Session 45 - 04:45 AM - 06:15 AM EST |
|
|
|
|
Translational Correlates Using Urinary Genomic Disease Burden to Assess Cretostimogene Grenadenorepvec: Analysis from the BOND-003 and CORE-001 Trials
Presented By: Sharada Mokkapati, MS, PhD
|
|
|
|
|
Cost-Effectiveness Analysis of Treatments for BCG-Unresponsive High-Risk NMIBC
Presented By: Amanda Myers, MD
|
|
|
|
|
